Suparma Tbk PT
Suparma Tbk PT is an Indonesian company engaged in the production and sale of paper products, primarily serving the packaging and printing industries.
Business. Suparma Tbk PT (SPMA.JK) is an Indonesian company operating in the Paper Products industry within the Basic Materials sector. The firm is headquartered in Indonesia and is primarily listed on the Indonesia Stock Exchange (IDX). Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Suparma Tbk PT (SPMA.JK) is an Indonesian company operating in the Paper Products industry within the Basic Materials sector. The firm is headquartered in Indonesia and is primarily listed on the Indonesia Stock Exchange (IDX). Specific details regarding its operating segments and geographic revenue mix are not available.
Suparma Tbk PT maintains a relatively strong liquidity position, with a current ratio of 2.0, indicating that its current assets exceed its current liabilities by a factor of two. The company's liquidity FPT (free cash flow to total debt) is not explicitly provided, but its free cash flow of 187.1 billion IDR and total liabilities of 1.17 trillion IDR suggest a moderate ability to service debt obligations. The company's price-to-book ratio of 0.34 indicates that its market value is significantly below its book value, which may reflect market skepticism about its asset quality or future earnings potential.
In terms of profitability, Suparma Tbk PT reports a return on equity (ROE) of 4.27% and a return on assets (ROA) of 2.9%. These figures are below the typical thresholds for strong performance in the Paper Products industry, suggesting that the company is not generating returns that significantly outpace its cost of capital. The company's operating margin, calculated as operating income of 181.5 billion IDR divided by revenue of 2.74 trillion IDR, is approximately 6.6%, which is in line with the industry median of 6.5%.
The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. Geographically, the company is primarily exposed to the Indonesian market, with no significant international operations disclosed. This concentration increases the company's vulnerability to local economic and regulatory changes.
Suparma Tbk PT's growth trajectory appears to be modest. The company's capital expenditure of -44.85 billion IDR (negative, indicating a reduction in capital spending) and its free cash flow of 187.1 billion IDR suggest a focus on maintaining operations rather than aggressive expansion. The outlook for the current fiscal year indicates a slight increase in revenue, but the magnitude of the increase is not specified. The company's net income of 106.23 billion IDR and operating income of 181.5 billion IDR suggest stable, but not robust, earnings performance.
The company faces several risk factors, including a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt indicates that the company's cash reserves are insufficient to cover its long-term obligations. The debt-to-equity ratio of 0.29 suggests a relatively conservative capital structure, but the company's price-to-book ratio of 0.34 indicates that the market may be undervaluing its assets. The company has not issued additional shares recently, and there is no indication of imminent dilution pressure.
Recent events and filings do not provide specific details about the company's strategic initiatives or major operational changes. The company's 10-K filing and other disclosures do not mention any significant new projects, partnerships, or regulatory challenges that would impact its near-term performance. The absence of recent major events suggests a stable but unremarkable operational environment.
- Suparma Tbk PT has a current ratio of 2.0, indicating strong short-term liquidity.
- The company's ROE of 4.27% and ROA of 2.9% are below industry benchmarks, suggesting suboptimal returns.
- The company's revenue is concentrated in a single business segment and geographic market, increasing its exposure to local risks.
- The company's capital expenditure is negative, indicating a reduction in investment, and its free cash flow is positive, suggesting operational efficiency.
- The company faces a medium liquidity risk and a low dilution risk, with no significant recent events affecting its operations.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Suparma Tbk PT Market data — financials · 2026-05-29